China Life Private Equity

  • Vazyme Biotech closes RMB550m Series C round

    Vazyme Biotech announced the completion of 550 million yuan Series C round of financing, exclusively led by China Life Private Equity, with participation from Sherpa Venture Capital and other institutions.
    Established in 2012, Vazyme Biotech, Vazyme Biotech is one of the few high-tech enterprises in China that has independent research and development capabilities for key raw materials in biotech